Towards the identification of molecular pathways predicting response to vedolizumab (Entyvio®) in Crohn*s disease deploying Systems Medicine: BullsEye Study

Towards the identification of molecular pathways predicting response to vedolizumab (Entyvio®) in Crohn*s disease deploying Systems Medicine: BullsEye Study - Identification op predictors of response to vedolizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50386

Enrollment

Registered

2017-09-28

Start date

2017-12-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease inflammatory bowel disesae

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult anti-TNF therapy naïve luminalCrohn*s disease patients in whom with vedolizumab therapy is initiated

Exclusion criteria

Exclusion criteria: Hospitalized patients or patients in need of surgery Active perianal disease Prior biological use

Design outcomes

Primary

Measure	Time frame
To identify biomarkers predicting response to vedolizumab in patients with CD	—

Secondary

Measure	Time frame
-Clinical response at 20 weeks, after induction therapy with vedolizumab defined as a reduction in the Harvey Bradshaw Index (HBI) score of at least 3 points -To gain insight in pathways, associated with (non)reponse to vedolizumab in patients with CD -Remission at 20 weeks, defined as a HBI	—

Countries

Netherlands

Outcome results